Orexin agonists have been approved for the treatment of a type of narcolepsy, yet they could also treat conditions across the health spectrum. When US regulators approved a treatment for narcolepsy in ...

The FDA should create an expedited pathway for clinical tests targeting emerging drug threats, write Dr. Shravani Durbhakula and Jeremy Kourvelas.

Phathom Pharmaceuticals (PHAT) announced the FDA's establishment of a public docket to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated ...

When voters rate the economy and the president negatively just weeks before Election Day, the incumbent party is vulnerable, and that’s certainly the case in the latest Fox News survey. The economic ...

Five weeks after the FDA approved a pill that extends survival in metastatic pancreatic cancer, one of the physicians who led ...

The latest data on the midterm elections, presidential approval and more. 59 new polls added conducted Oct. 28 to Nov. 1. 74 new polls added 19 new polls added 44 new polls added 42 new polls added ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Foundayo is an oral GLP-1 medicine approved for weight loss. It first earned approval in the U.S. in April and has been fairly successful since. What's important about Foundayo is that it isn't just ...

The companies announced the deal in November last year, underscoring a wave ⁠of consolidation among paint makers to save money in the face of rising costs and amid uncertainties created by US ...

AstraZeneca is the latest in a series of large biopharmas to adopt insitro’s platform. (Li Ziheng/Xinhua via Getty Images) AstraZeneca is paying insitro $40 million upfront to find novel drug targets ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, ...